Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ABBV stock price vs LH: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at LH's multiple
Needs LH P/E.
Implied fair value · at ABBV's multiple
Needs ABBV P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
AbbVie Inc. · implied price per share
Bear
$74.44
Base
$92.88
Bull
$117.70
LABCORP HOLDINGS INC. · implied price per share
Bear
$94.57
Base
$113.84
Bull
$148.04
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Pfizer Inc.
ABBV vs PFE
Johnson & Johnson
ABBV vs JNJ
Merck & Co., Inc.
ABBV vs MRK
Eli Lilly and Company
ABBV vs LLY
Amgen Inc.
ABBV vs AMGN
Gilead Sciences, Inc.
ABBV vs GILD
THERMO FISHER SCIENTIFIC INC.
ABBV vs TMO
DANAHER CORP /DE/
ABBV vs DHR
QUEST DIAGNOSTICS INC
ABBV vs DGX
WEST PHARMACEUTICAL SERVICES INC
ABBV vs WST
BAXTER INTERNATIONAL INC
ABBV vs BAX
MCKESSON CORP
ABBV vs MCK
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe ABBV’s premium multiples are justified by its higher margins, ROIC, and durable growth profile, then hold or accumulate selectively; otherwise, the current data argue for caution because the implied price, DCF range, and relative valuation all point to substantial downside from $245.10.
ABBV trades at a steep premium to LH on earnings, sales, and enterprise-value multiples, yet the provided implied price suggests meaningful downside from the current quote. The current price is also above the top of the DCF range and only modestly within the historical trading band, so valuation support looks limited from the supplied data.
Supporting Metrics
